BlackRock Group’s Amicus Therapeutics FOLD Stock Holding History

BlackRock Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$416K	Buy	83,733 +9,888	+13%	+$68.4K	﹤0.01%	2420
2016 Q3	$546K	Buy	73,845 +1,821	+3%	+$12.3K	﹤0.01%	2286
2016 Q2	$393K	Buy	72,024 +2,681	+4%	+$18.7K	﹤0.01%	2350
2016 Q1	$587K	Buy	69,343 +31,166	+82%	+$221K	﹤0.01%	2170
2015 Q4	$370K	Sell	38,177 -813	-2%	-$7.33K	﹤0.01%	2308
2015 Q3	$545K	Buy	38,990 +10,656	+38%	+$167K	﹤0.01%	2175
2015 Q2	$401K	Buy	28,334 +10,838	+62%	+$130K	﹤0.01%	2345
2015 Q1	$190K	Sell	17,496 -36,619	-68%	-$323K	﹤0.01%	2510
2014 Q4	$450K	Buy	54,115 +40,261	+291%	+$276K	﹤0.01%	2274
2014 Q3	$82K	Buy	+13,854	New	+$72.6K	﹤0.01%	2614

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlackRock Group's FOLD Position: Q4 2016 in Review

BlackRock Group increased its Amicus Therapeutics (FOLD) stake by 13% in Q4 2016, buying an estimated $68.4K and bringing the position to 83,733 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

BlackRock Group first reported a position in FOLD in Q3 2014 and has held it in 10 quarters since. The position peaked at $587K in Q1 2016. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

BlackRock Group held 83,733 shares of Amicus Therapeutics worth $416K as of Q4 2016.
BlackRock Group bought 9,888 Amicus Therapeutics shares in Q4 2016, an estimated $68.4K.
Amicus Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2420 holding.
BlackRock Group first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 10 quarters since.
BlackRock Group's Amicus Therapeutics position peaked at $587K in Q1 2016.
135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.